Mar 31, 2015
1.1 Accounting Standard (AS-17) "Segment Reporting":
The Company has identified business segments as its primary segment.
Business segments are primarily Healthcare and Fine Chemicals Revenues
and expenses directly attributable to segments are reported under each
reportable segment. Expenses which are not directly identifiable to
each reportable segment have been allocated on the basis of associated
revenues of the segment and manpower efforts. All other expenses which
are not attributable to segments have been disclosed as unallocable
expenses. Assets and liabilities that are directly attributable or
allocable to segments are disclosed under each reportable segment. All
other assets and liabilities are discolosed as unallocable. Fixed
assets that are used interchangeably amongst segments are not allocated
to primary segments.
1.2 Accounting Standard ( As-18) " Related Party Disclosures":
a) Entities in which the Company has substantial Interest Emmessar
Technologies Limited
b) Key Management Personnel and their relatives
i) MSR Ayyangar - Managing Director
ii) Dr. Anuradha Raghavan - Daughter of MSR Ayyangar
iii) Dr. Sarada Raghavan - Daughter of MSR Ayyangar
1.3 Due to/ from parties are subject to confirmation.
1.4 In the opinion of the Board all the current Assets, Loans and
Advances deposits are realisable at value stated in ordinary course of
business which are atleast equal to the amount at which they are stated
in the books unless otherwise stated.
1.5 As no dividend has been declared during the current year as well
as previous year, the Company has not remitted any dividend in foreign
currency to its non resident shareholders during the current year as
well as previous year
1.6 The company is in the proces of evaluating various business
opportunities within the pharmaceutical and health care industry. These
business plans when implemented will have positive impact on the
financial performance and absorb all the lossess. Accordingly, the
company is of the view that going concern assumption is not affected.
1.7 Previous year figures have been regrouped/ reclassified to
correspond with the curent year classification disclosure
Mar 31, 2014
Particulars
Year Ended31.3.2014 Year Ended 31.3.2013
1.1 COMMITMENTS &
CONTINGENT LIABILITIES
a) Estimated Amount of
Contract remains to be
executed and not provided
for in the accounts NIL NIL
b) Claims against the
Company not acknowledges
as Debts NIL NIL
D. Other Long Term Benefits
The Company''s does not have any other Long Term benefits
1.2 Accounting Standard (AS-17) "Segment Reporting":
The Company has identified business segments as its primary segment.
Business segments are primarily Healthcare and Fine Chemicals Revenues
and expenses directly attributable to segments are reported under each
reportable segment. Expenses which are not directly identifiable to
each reportable segment have been allocated on the basis of associated
revenues of the segment and manpower efforts.All other expenses which
are not attributable to segments have been disclosed as unallocable
expenses. Assets and liabilities that are directly attributable or
allocable to segments are disclosed under each reportable segment. All
other assets and liabilities are discolosed as unallocable. Fixed
assets that are used interchangeably amongst segments are not allocated
to primary segments.
Particulars - for the year ended March 31, 2014
1.3 Accounting Standard ( As-18) " Related Party Disclosures":
a) Entities in which the Company has substantial Interest Emmessar
Technologies Limited
b) Key Management Personnel and their relatives
i) MSR Ayyangar - Managing Director
ii) Dr. Anuradha Raghavan - Daughter of MSR Ayyangar
iii) Dr. Sarada Raghavan - Daughter of MSR Ayyangar Details of the
transactions with above parties
Financial transactions have been carried out in the ordinary course of
business and/ or in discharge of contractual obligations
1.4 Due to/ from parties are subject to confirmation.
1.5 In the opinion of the Board all the current Assets, Loans and
Advances deposits are realisable at value stated in ordinary course of
business which are atleast equal to the amount at which they are stated
in the books unless otherwise stated.
1.6 As no dividend has been declared during the current year as well
as previous year, the Company has not remitted any dividend in foreign
currency to its non resident shareholders during the current year as
well as previous year
1.7 Value of Imports on CIF Basis
1.8 The company is in the proces of evaluating various business
opportunities within the pharmaceutical and health care industry. These
business plans when implemented will have positive impact on the
financial performance and absorb all the lossess. Accordingly, the
company is of the view that going concern assumption is not affected.
1.9 Previous year figures have been regrouped/ reclassified to
correspond with the curent year classification disclosure
Mar 31, 2013
A. Corporate Information
Emmessar Biotech & Nutrition Limited is a public limited company
domiciled in India incorporated under the provisions of the Companies
Act, 1956. Its shares are listed in the Bombay Stock Exchange. The
Company is engaged in manufacturing and marketing Healthcare /
pharmaceuticals products and chemicals. The Company caters to both
domestic and international markets.
1.1 Accounting Standard (AS-17) "Segment Reporting":
The Company has identified business segments as its primary segment.
Business segments are primarily Healthcare and Fine Chemicals Revenues
and expenses directly attributable to segments are reported under each
reportable segment. Expenses which are not directly identifiable to
each reportable segment have been allocated on the basis of associated
revenues of the segment and manpower efforts. All other expenses which
are not attributable to segments have been disclosed as unallowable
expenses. Assets and liabilities that are directly attributable or
allocable to segments are disclosed under each reportable segment. All
other assets and liabilities are disclosed as unallowable. Fixed
assets that are used interchangeably amongst segments are not allocated
to primary segments.
1.2 Accounting Standard ( As-18) " Related Party Disclosures":
a) Entities in which the Company has substantial Interest Emissary
Technologies Limited
b) Key Management Personnel and their relatives
i) MSR Ayyangar - Managing Director
ii) A.V.Vardharajan - Executive Director ( Worked up to January 2013)
iii) A.V. Saranagaranjan - Brother of A.V. Vardharanjan( Worked up to
October 2012)
iv) Vasudevan Raghavan - Son of MSR Ayyangar (Worked up to August 2012)
1.3 The Company has incurred net loss during the year and it has also
brought forward unabsorbed depreciation and business loss from previous
years as per books of account as well as under the Income Tax Act,
1961. In view thereof no provision for Income Tax including Minimum
Alternate Tax on Book Profits has been made in the accounts. However
net Deferred Tax Asset has not been recognized, as there is uncertainty
of the realization thereof in the future.
1.4 Due to/ from parties are subject to confirmation.
1.5 In the opinion of the Board all the current Assets, Loans and
Advances deposits are realizable at value stated in ordinary course of
business which are at least equal to the amount at which they are stated
in the books unless otherwise stated.
1.6 As no dividend has been declared during the current year as well
as previous year, the Company has not remitted any dividend in foreign
currency to its nonresident shareholders during the current year as
well as previous year.
Mar 31, 2012
A. Corporate Information
Emmessar Biotech & Nutrition Limited is a public limited company
domiciled in India incorporated under the provisions of the Companies
Act, 1956. Its shares are listed in the Bombay Stock Exchange. The
Company is engaged in manufacturing and marketing Healthcare /
pharmaceuticals products and chemicals. The Company caters to both
domestic and international markets.
1.1 COMMITMENTS & CONTINGENT LIABILITIES
a) Estimated Amount of Contract remains to
be executed and not provided for in the
accounts (Net of Payments Made) in respect
of Capital Assets NIL NIL
b) Claims against the Company not acknowledges as Debts NIL NIL
D. Other Long Term Benefits
The Company's does not have any other Long Term benefits
1.2 Accounting Standard (AS-17) "Segment Reporting":
The Company has identified business segments as its primary segment.
Business segments are primarily Healthcare and Fine Chemicals Revenues
and expenses directly attributable to segments are reported under each
reportable segment. Expenses which are not directly identifiable to
each reportable segment have been allocated on the basis of associated
revenues of the segment and manpower efforts.AII other expenses which
are not attributable to segments have been disclosed as unallocable
expenses. Assets and liabilities that are directly attributable or
allocable to segments are disclosed under each reportable segment. All
other assets and liabilities are discolosed as unallocable. Fixed
assets that are used interchangeably amongst segments are not allocated
to primary segments.
1.3 The Company has incurred net loss during the year and it has also
brought forward unabsorbed depreciation and business loss from previous
years as per books of account as well as under the Income Tax Act,
1961. In view thereof no provision for Income Tax including Minimum
Alternate Tax on Book Profits has been made in the accounts. However
net Deferred Tax Asset has not been recognised, as there is uncertanity
of the realization thereof in the future.
1.4 Due to/ from parties are subject to confirmation.
1.5 In the opinion of the Board all the current Assets, Loans and
Advances deposits are realisable at value stated in ordinary course of
business which are atleast equal to the amount at which they are stated
in the books unless otherwise stated.
1.6 As no dividend has been declared during the current year as well
as previous year, the Company has not remitted any dividend in foreign
currency to its non resident shareholders during the current year as
well as previous year.
1.7 The Revised Schedule VI has become effective from 1st April 2011
for the preparation of financial statements. This has significantly
impacted the disclosure and presentation made in the financial
statements. Previous Years figures have been regrouped / reclassified
wherever necessary to correspond with the current year's
classification/ disclosure.
Mar 31, 2010
1. a) Contingent Liabilities: NIL
b) Estimated amount of contracts remaining to be executed on
capital account and not provided for (Net of Advances) : NIL
2. Registration is pending for 2 residential flats included in
buildings shown in the Schedule III of Fixed Assets.
3. The Company has incurred net loss during the year and it has also
brought forward unabsorbed depreciation and business losses from
previous years as per books of account as well as under the Income Tax
Act, 1961. In view thereof, no Provision for Income Tax including
Minimum Alternate Tax on Book Profits has been made in the accounts.
However, Deferred Tax Asset has not been recognised, as there is
uncertainty of the realization thereof in the future.
4. Sundry Debtors include Rs.5.82 lakhs due from customers outstanding
for a considerable long period. During the year the company has
recovered Rs. 1.23 Lacs from these customers. In the opinion of the
management the entire amount is recoverable and hence considered good.
5. Quantitative information as required by paragraph 3 of Part II of
Schedule VI to the Companies Act, 1956 (As Certified by the
Management):
a) LICENSED AND INSTALLED CAPACITY - NIL b) PRODUCTION
The aforesaid remuneration does not exceed Rs. 100000/ per month or Rs.
1200000/- per annum (the effective capital of the Company is Rs. 1
Crore or more but less than Rs. 5 Crores) as provided in Part II of
Schedule XIII to the Companies Act, 1956 vide Circular No. GSR 36(E)
issued in connection with Remuneration Payable by the Companies having
no profits or inadequate profits as payment of remuneration is approved
by a resolution passed by the members in the General Meeting of the
Company and the Company has not made any default in repayment of any of
its debts or interest payable thereon.
6. EARNING PER SHARE
The Numerator and Denominator used to calculate Basic / Diluted Earning
Per Share and the Calculated Basic / Diluted Earning Per Share is as
under.
7. RELATED PARTY DISCLOSURES: List of related parties.
a) Parties where control exists à None b) Other related parties with
whom transactions have taken place during the year:
i) Emmessar Technologies Limited.
c) Key Management Personnel and their Relatives
i) MSR Ayyangar (Managing Director)
ii) A.V. Vardharajan (Executive Director)
iii) A.V. Sarangarajan(Brother of A.V. Vardharajan)
iv) Vasudevan Raghavan (Son of MSR Ayyangar)
Details of remuneration to Managing Director & Executive Director are
disclosed at Note No. 14 herein before.
8. In the opinion of the Management, the Current Assets, Loans and
Advances are expected to produce at least equal to the amount at which
they are stated in the Balance Sheet in the ordinary course of
business.
9. Dues to/ from parties are subject to confirmation.
10. As no dividend has been declared during the current year as well as
previous year, the Company has not remitted any dividend in foreign
currency to its non- resident shareholders during the current year as
well as previous year.
11. In the opinion of the Management, the provisions for all known
undisputed liabilities are adequate and is neither in excess nor short
of the amount reasonably considered necessary.
12. There is no amount due to "Micro or Small Enterprises" and Medium
Enterprises Act, 2006. Further no interest is paid / payable in terms
of section 16 of the said Act. The information regarding dues to
"Micro or Small Enterprises" are given to the extent such parties have
been identified on the basis of information available with the Company.
13. Additional information pursuant to the provision of Part IV of
Schedule VI to the Companies Act, 1956, pertaining to Balance Sheet
Abstract and Companys General Business Profit is annexed hereto.
14. Schedules "I" to "XI" form integral part of the accounts and have
been duly authenticated.
15. Previous year figures have been reclassified / regrouped / recasted
/ rearranged wherever considered necessary to conform with the
classification of the current year and to make them comparable with the
current years figures.
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article